Karolinska Development's portfolio company Umecrine Cognition presents preclinical data showing that golexanolone reduces neuroinflammation and counteracts motor symptoms
STOCKHOLM, SWEDEN – 11 January 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented results from a preclinical study showing that the drug candidate golexanolone has a suppressive effect on neuroinflammation in the cerebellum, leading to the cessation of disease-related motor disturbances. The study further enhances understanding of golexanolone's mechanism of action and highlights its potential to treat symptoms related to movement and coordination. The study was carried out in collaboration with Dr Vincente Felipo at the Laboratory of Neurobiology, Centro de Investigación Principe Felipe, Valencia.
Neuroinflammation is a complex process that occurs normally in the central nervous system, where immune cells are activated to maintain brain functions and counteract disease. When this process becomes unbalanced, neurological impairment occurs, as seen in conditions such as hyperammonemia and hepatic encephalopathy. These conditions cause, among other symptoms, confusion, fatigue, dizziness, impaired coordination and cognition, which have a significant negative impact on the quality of life of the affected person. Treatments that specifically limit harmful neuroinflammation are therefore desirable.
Using a preclinical disease model that induces neuroinflammation, image analyses showed that activation of immune cells in the cerebellum – the brain area that controls movement and coordination – was attenuated by treatment with golexanolone, compared to a control group. Further analyses showed that locomotion and coordination were normalised after treatment with golexanolone. In conclusion, the results indicate that harmful neuroinflammation and disease-related motor symptoms could be alleviated by correcting GABAA receptor activity with golexanolone.
"We are pleased with Umecrine Cognition's continued progress and are positive to the continued mapping of golexanolone's mechanism of action. The results indicate that golexanolol may be of great importance as a future treatment for inflammatory diseases of the CNS," said Viktor Drvota, CEO, Karolinska Development.
Karolinska Development's direct ownership interestin Umecrine Cognition amounts to 70 percent.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: email@example.com
Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: firstname.lastname@example.org
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Ahold Delhaize share buyback update16.8.2022 08:00:00 CEST | Press release
Zaandam, the Netherlands, August16, 2022 – Ahold Delhaize has repurchased 254,408 of its common shares in the period from August 8, 2022 up to and including August 12, 2022. The shares were repurchased at an average price of € 27.21 per share for a total consideration of € 6.9 million. These repurchases were made as part of the € 1 billion share buyback program announced on November 15, 2021. The total number of shares repurchased under this program to date is 20,621,088 common shares for a total consideration of € 561.6 million. Download the share buyback transactions excel sheet for detailed individual transaction information from https://www.aholddelhaize.com/en/investors/share-buyback-programs/2022/ This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs.
Sanionas Kv7-program för epilepsi avanceras till leadoptimering16.8.2022 08:00:00 CEST | Pressemelding
PRESSMEDDELANDE 16 augusti 2022 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling, meddelar idag att bolaget har avancerat sitt lovande Kv7-program för epilepsi till fasen leadoptimering – den sista fasen av läkemedelsupptäckt innan en klinisk kandidat väljs ut. Thomas Feldthus, VD: ”Vi tror att vi har löst knäckfrågorna för att utveckla nästa generation av läkemedelskandidater av den här klassen, och vi ser en betydande potential att ta fram nya banbrytande epilepsibehandlingar. Finansiellt kan uppsidan vara avsevärd, att döma av vissa viktiga läkemedelsavtal som nyligen slutits på Kv7-området.” Miljontals människor runt om i världen påverkas i dag av epilepsi, en sjukdom som kännetecknas av återkommande krampanfall. Det medicinska behovet är stort, eftersom omkring 30 procent av patienterna inte svarar på behandling med konventionella läkemedel mot epilepsi. Läkemedel mot kramper kan desutom ha funktionshämmande biverkningar, som ofta måste minimeras genom no
Saniona progresses its Kv7 epilepsy program into Lead Optimization16.8.2022 08:00:00 CEST | Press release
PRESS RELEASE August 16, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that it has progressed its promising Kv7 epilepsy program into the Lead Optimization Phase, which is the last drug discovery phase before potential selection of a clinical candidate. Thomas Feldthus, CEO: “We believe that we have cracked the main challenges for making the next generation drug candidates of this class and see significant potential for delivering new breakthrough epilepsy treatments. The financial upside could be substantial based on very significant pharma deals recently executed in the Kv7 field”. Epilepsy, characterized by recurrent seizures, currently affects millions of people worldwide. There is a significant medical need as approximately 30% of patients are insensitive to treatment by conventional epilepsy medicines. Furthermore, anti-seizure therepy may cause disabling side effects and often require careful dose adjustment to minimize these. Kv7 ion ch
JULY VOLUME REPORT: STRONG PASSENGER RECOVERY, DROP IN CHANNEL FREIGHT MARKET16.8.2022 07:35:00 CEST | Press release
INVESTOR NEWS no. 24 - 16 August 2022 Ferry – freight: Total volumes in July 2022 were 6.2% below 2021. Activity was overall robust in freight markets except for parts of the Baltic Sea region and the Channel Dover Strait corridor. North Sea volumes were overall below 2021 as UK routes were on level while routes between Sweden and the Continent were below 2021. The latter decrease was due to lower automotive and paper volumes as well as high activity for these segments last year in July. Volumes in the Mediterranean network continued to grow reflecting a high level of Turkish industrial production and exports. Channel’s volumes were below 2021 following a decrease in total market volumes. Baltic Sea’s volumes were below 2021 due to the war in Ukraine. Volumes were mainly lower between Germany and Lithuania. For the last twelve months 2022-21, the total transported freight lane metres decreased 0.6% to 43.6m from 43.9m in 2021-20. Ferry – passenger: The number of passengers increased fi
JULI MÆNGDERAPPORT: STÆRKT PASSAGEROPSVING, NEDGANG I KANALENS FRAGTMARKED16.8.2022 07:35:00 CEST | pressemeddelelse
INVESTOR NEWS nr. 24 - 16. august 2022 Færge – fragt: De samlede mængder i juli 2022 var 6,2% lavere end i 2021. Aktiviteten var generelt robust på fragtmarkederne bortset fra dele af Østersø-regionen og Kanalens Doverstræde. North Seas mængder var samlet set lavere end i 2021, da ruterne til Storbritannien var på niveau, mens ruterne mellem Sverige og kontinentet var lavere end i 2021. Sidstnævnte nedgang skyldtes lavere bil- og papirmængder samt høj aktivitet for disse segmenter sidste år i juli. Mediterraneans mængder fortsatte med at stige, hvilket afspejler en fortsat høj tyrkisk industriproduktion og eksport. Channels mængder var lavere end i 2021 som følge af en nedgang i det samlede markeds mængder. Baltic Seas mængder var lavere end i 2021 på grund af krigen i Ukraine. Mængderne var primært lavere mellem Tyskland og Litauen. For de sidste 12 måneder 2022-21 var der en nedgang i det samlede antal transporterede fragt-lanemeter på 0,6% til 43,6 mio. fra 43,9 mio. i 2021-20. Færg